Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907663 | 0.87 | MEN1 (0.65) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL21233937 | 0.87 | MEN1 (0.65) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL14183971 | 0.86 | KMT2A (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL20734724 | 0.86 | KMT2A (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL29828465 | 0.86 | KMT2A (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL15514213 | 0.86 | KMT2A (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL6403394 | 0.86 | KMT2A (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL23224250 | 0.84 | HPGD (0.69) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL18774007 | 0.84 | KMT2A (0.61) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL12019303 | 0.84 | HPGD (0.73) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784995-A | Isotopic psychoactive substance labeled compound, preparation method and application thereof | 公安部第三研究所 | 2023-03-14 | — | — | CN | claimed |
| CN-115784994-A | Isotopic psychoactive substance labeled compound, preparation method and application thereof | 公安部第三研究所 | 2023-03-14 | — | — | CN | claimed |
| CN-114478389-A | Isotopic psychoactive substance labeled compound, preparation method, application and application thereof | 公安部第三研究所 | 2022-05-13 | — | — | CN | claimed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| CN-115784995-A | Isotopic psychoactive substance labeled compound, preparation method and application thereof | 公安部第三研究所 | 2023-03-14 | — | — | CN | disclosed |
| CN-115784994-A | Isotopic psychoactive substance labeled compound, preparation method and application thereof | 公安部第三研究所 | 2023-03-14 | — | — | CN | disclosed |
| CN-114478389-A | Isotopic psychoactive substance labeled compound, preparation method, application and application thereof | 公安部第三研究所 | 2022-05-13 | — | — | CN | disclosed |
| EP-3319963-B1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-08 | — | — | EP | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-8981049-B2 | Aziridine mediated native chemical ligation | WASHINGTON STATE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-6306884-B1 | ANTICOAGULANTS AND BLOOD COAGULATION FACTOR | BERLEX LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6034103-A | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6004981-A | HUMAN FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 1999-12-21 | — | — | US | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5296604-A | Proline derivatives and compositions for their use as inhibitors of HIV protease | MILES INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-4098705-A | ADDITIVE FOR LUBRICANTS | ASAHI DENKA KOGYO K.K. (JP) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ALDH1A1 4236/4885SMN1; SMN2 2633/4885HPGD 905/4885 |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | ALDH1A1 2348/4885SMN1; SMN2 3075/4885HPGD 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.